Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference.

Monday, Jan 12, 2026 9:18 am ET1min read
PCSA--

Processa Pharmaceuticals announced that CEO George Ng and CSO Patrick Lin will attend the 44th Annual J.P. Morgan Healthcare Conference to discuss their clinical pipeline, including the ongoing Phase 2 study of NGC-Cap in advanced breast cancer. Preliminary data show NGC-Cap increases exposure to cancer-killing metabolites while maintaining a comparable safety profile to standard capecitabine monotherapy.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet